Valeo Financial Advisors LLC Invests $225,000 in Biogen Inc. $BIIB

Key Points

• Valeo Financial Advisors LLC has invested $225,000 in Biogen Inc. by acquiring 1,794 shares, reflecting growing interest from institutional investors in the biotechnology sector.
• Research analysts have mixed ratings for Biogen, with a current consensus rating of "Hold" and a target price averaging $180.15, indicating cautious optimism for future stock performance.
• Biogen reported strong earnings for the last quarter, achieving $5.47 EPS and generating $2.65 billion in revenue, exceeding analysts' expectations by a notable margin.

Valeo Financial Advisors LLC bought a new stake in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 1,794 shares of the biotechnology company's stock, valued at approximately $225,000.

Several other large investors have also recently modified their holdings of the stock. Opal Wealth Advisors LLC bought a new position in Biogen during the first quarter valued at approximately $26,000. Vision Financial Markets LLC bought a new stake in Biogen during the first quarter valued at about $27,000. Greykasell Wealth Strategies Inc. purchased a new stake in shares of Biogen during the first quarter worth about $27,000. Zions Bancorporation National Association UT purchased a new position in shares of Biogen in the first quarter worth $29,000. Finally, Private Trust Co. NA grew its position in shares of Biogen by 74.8% during the first quarter. Private Trust Co. NA now owns 229 shares of the biotechnology company's stock valued at $31,000 after purchasing an additional 98 shares in the last quarter. Hedge funds and other institutional investors own 87.93% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the stock. Piper Sandler increased their price target on shares of Biogen from $115.00 to $118.00 and gave the company a "neutral" rating in a report on Friday, September 12th. William Blair reaffirmed an "outperform" rating on shares of Biogen in a research note on Wednesday, September 24th. Truist Financial initiated coverage on Biogen in a research report on Monday, July 21st. They set a "hold" rating and a $142.00 target price for the company. Royal Bank Of Canada cut their price target on Biogen from $219.00 to $217.00 and set an "outperform" rating on the stock in a research note on Wednesday. Finally, Morgan Stanley upped their price target on shares of Biogen from $144.00 to $149.00 and gave the stock an "equal weight" rating in a research report on Friday. Eleven research analysts have rated the stock with a Buy rating, nineteen have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Biogen presently has a consensus rating of "Hold" and a consensus target price of $180.15.

Biogen Stock Down 2.0%

Shares of BIIB stock opened at $146.57 on Friday. The stock's 50-day simple moving average is $140.21 and its 200-day simple moving average is $131.23. The firm has a market capitalization of $21.49 billion, a PE ratio of 14.01, a P/E/G ratio of 1.18 and a beta of 0.13. Biogen Inc. has a fifty-two week low of $110.04 and a fifty-two week high of $194.13. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.79 and a current ratio of 2.50.

Biogen (NASDAQ:BIIB - Get Free Report) last issued its earnings results on Thursday, July 31st. The biotechnology company reported $5.47 EPS for the quarter, beating analysts' consensus estimates of $3.93 by $1.54. Biogen had a return on equity of 13.85% and a net margin of 15.31%.The firm had revenue of $2.65 billion for the quarter, compared to analyst estimates of $2.32 billion. During the same quarter in the prior year, the firm earned $5.28 earnings per share. Biogen's revenue for the quarter was up 7.3% on a year-over-year basis. Biogen has set its FY 2025 guidance at 15.500-16.000 EPS. Equities analysts expect that Biogen Inc. will post 15.83 earnings per share for the current year.

Insider Activity

In related news, insider Priya Singhal sold 517 shares of the firm's stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $133.55, for a total transaction of $69,045.35. Following the completion of the transaction, the insider owned 5,772 shares of the company's stock, valued at $770,850.60. This trade represents a 8.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.18% of the stock is currently owned by company insiders.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.